● Recruiting

POLA-R-CHP in the First-line Treatment of Transformed DLBCL

Condition: Transformed Lymphoma · Sponsor: Fudan University

PhasePhase 2

Planned participants20

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

This study aims to evaluate efficacy and safety of POLA-R-CHP in the treatment of patients with transformed DLBCL.

This description comes directly from the study's public registry record.

Talk to the study team

Yizhen Liu, M.D., Ph.D. · 021-64175590 · aliuyz@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06743945